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Clinical significance of intrahepatic hepatitis C
virus levels in patients with chronic HCV infection
G H Haydon, L M Jarvis, C S Blair, P Simmonds, D J Harrison, K J Simpson, P C Hayes
Abstract
Background—The clinical significance of
a single assessment of circulating hepatitis
C virus (HCV) RNA and its relation to the
level of intrahepatic HCV RNA remains
unclear.
Aims—To investigate the relation between
intrahepatic HCV levels and clinicopatho-
logical characteristics of chronic HCV
infection.
Patients—Ninety eight consecutive pa-
tients with chronic HCV infection were
studied; none had received á interferon
therapy. Of these, 12 patients were repeat-
edly negative for HCV RNA in serum by
reverse transcriptase polymerase chain
reaction (RT-PCR).
Methods—After diagnostic laparoscopy
and liver biopsy, semiquantitative analysis
of intrahepatic HCV RNA levels was
carried out by limiting dilution of HCV
cDNA.HCV genotypes were assessed in 96
patients by restriction fragment length
polymorphism analysis of HCV cDNA.
Results—Ten out of 12 patients who were
RT-PCR negative for HCV RNA in serum
were RT-PCR positive in liver; however,
this group had a significantly lower intra-
hepatic HCV level and serum aminotrans-
ferase level than the remaining 86
patients. Histological severity (cirrhosis:
n=10); histological activity index; HCV
genotype (genotype 1: n=41; genotype 2:
n=12; genotype 3: n=36; genotype 4: n=7);
mode of infection (intravenous drug
abuse: n=58; post-transfusion: n=10; hae-
mophiliac: n=4; sporadic: n=26) and alco-
hol abuse did not aVect the intrahepatic
virus level. There was no correlation
between patient age, duration of infection,
and intrahepatic HCV level.
Conclusions—Intrahepatic virus levels
were not determined by host factors (age
of patient, mode or duration of infection)
or by virus factors (HCV genotype).
Repeatedly negative RT-PCR for HCV
RNA in serum does not indicate absence
of HCV from the liver.
(Gut 1998;42:570–575)
Keywords: intrahepatic hepatitis C virus; chronic
hepatitis C virus infection
Hepatitis C virus (HCV) is the predominant
cause of post-transfusion and sporadic non-A
non-B hepatitis worldwide.1–5 Approximately
95% of HCV infected individuals can be iden-
tified by third generation anti-HCV testing.6 7
However, this test does not indicate active
infection, and there is considerable controversy
as to the biochemical, virological, and histo-
logical definitions of a “past infection”.
Initial, fundamental studies suggested that
negative serum HCV cDNA polymerase chain
reaction (PCR) results in recombinant immu-
noblot assay (RIBA) positive individuals corre-
lated with the absence of inflammation in liver
biopsy specimens.8 The serum HCV cDNA
PCR result was therefore a sensitive and
specific marker of liver disease in anti-HCV
positive subjects, independent of serum alanine
aminotransferase (ALT) values; true healthy
carriers of HCV did not exist. Following these
reports, it has been recommended that patients
negative in serum for HCV cDNA do not
undergo routine liver biopsy; furthermore, that
those with persisting abnormal liver function
tests should be screened for other liver diseases
(for example, autoimmune chronic active
hepatitis or haemochromatosis), while those
with normal liver function tests ought to be
followed up annually until the natural history
of the disease is better documented.9
Many previous studies have examined the
significance of serum HCV levels and have
shown a wide range of clinicopathological
relations10–18; however, there are fewer data
examining intrahepatic HCV levels and their
associations.19–29 In general, previous data have
not shown any correlation between HCV levels
in the liver and other demographic factors such
as sex, age, duration of illness, and risk factors.
There is a suggestion that some genotypes, in
particular genotype 1b, may be associated with
higher serum and liver virus levels30–32; but in
contrast with serum studies, intrahepatic stud-
ies have not shown any correlation between
HCV RNA levels and liver injury.19–29
To address these issues further, we deter-
mined the clinical, histological, and intrahe-
patic virological profile of patients with serum
repeatedly negative for HCV RNA by reverse
transcriptase (RT) PCR; we then compared
this population with a control population of
patients whose serum was repeatedly positive
for HCV by RT-PCR. Concurrently, we inves-
tigated the relation between intrahepatic HCV
levels and the clinicopathological characteris-
tics of chronic HCV infection.
Patients and methods
PATIENTS
Ninety eight consecutive patients (69 male;
mean age 37.8 ± 8 years) with chronic HCV
infection were included in the study; none had
received á interferon therapy. All patients were
positive for anti-HCV antibodies by second
generation enzyme immunoassay (EIA-2,
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and third generation recombinant immunoblot
assay (RIBA-3, Chiron, Emeryville, Califor-
nia). Fifty eight patients had acquired their
infection through abuse of intravenous drugs
(IVDA), 10 had acquired infection from red
cell concentrate transfusions, four were haemo-
philiacs transfused with infected blood prod-
ucts, and in 26 there were no obvious risk fac-
tors for infection.
At the time of admission to hospital, each
patient was questioned about the likely dura-
tion of their infection (in the case of the IVDA
group, this was calculated from the year of first
injection). Serum aminotransferase was meas-
ured on the day of diagnostic laparoscopy.
A small portion of the liver biopsy specimen
taken at laparoscopy was washed in ice cold
normal saline, blotted on a sterile swab, and
immediately frozen in liquid nitrogen and
stored at −70°C for future use. The remainder
of the biopsy specimen was used for histologi-
cal analysis.
Serum samples were obtained, separated
within three hours of collection on the day of
laparoscopy, and stored at −70°C. All samples
were stored for a maximum of three to six
months before analysis.
HCV RNA EXTRACTION FROM SERUM SAMPLES
RNA was extracted from 0.1 or 0.5 ml of
stored serum from each of the patients as pre-
viously described.33 34 Briefly, the RNA was
pelleted by centrifugation at 100 000 g for 90
minutes at 4°C and incubation at 37°C for two
hours with 1 mg/ml proteinase K in the
presence of 40 µg/ml polyadenylic acid, 0.5%
sodium dodecyl sulphate (SDS), 0.1 M NaCl,
50 mM Tris HCl (pH 8.0), and 1 mM EDTA.
RNA was extracted with phenol; after centrifu-
gation, the supernatant was re-extracted suc-
cessively with phenol and chloroform-isoamyl
alcohol (50:1). Nucleic acid was precipitated
by the addition of one tenth volume of sodium
acetate (pH 5.2) and two volumes of ethanol.
The dried pellet was resuspended in 25 µl of
diethyl pyrocarbonate treated water.
HCV RNA EXTRACTION FROM LIVER BIOPSY
SAMPLES
RNA extraction from liver biopsy samples was
carried out using a commercial modification
(RNAzol, Biogenesis Ltd, Bournemouth, UK)
of the single step method of RNA isolation by
acid guanidinium thiocyanate-phenol-chloro-
form extraction.34
Tissue samples were homogenised with
RNAzol solution (phenol derivative); RNAwas
extracted by centrifugation at 12 000 g for 15
minutes at 4°C with chloroform. RNA was
precipitated by addition of isopropanol to the
aqueous phase; the samples were stored for 15
minutes at 4°C and then centrifuged for 15
minutes at 12 000 g (4°C); the RNA precipi-
tates formed a white-yellow pellet at the
bottom of the tube. The supernatant was
removed, and the RNA pellet was washed once
with 75% ethanol by vortexing and centrifuged
for eight minutes at 7500 g (4°C). The dried
pellet was resuspended in 25 µl diethylpyrocar-
bonate treated water.
RT-PCR AND VIRAL GENOTYPING
RNA was reverse transcribed and ampli-
fied using nested primers matching the
5'-NCR.34 Product DNAs were cleaved with
restriction enzymes Hae-111/Rsa-1 and
Mva-1/Hinf-1.35–39 The fragments were
Table 1 Comparison of demographic and virological data of serum RT-PCR positive and
negative patients, all of whom have persistent infection
Host or virus parameter Serum RT-PCR negative Serum RT-PCR positive p Value
Age (y) 35.2 (6) 37.8 (8) NS
Sex (M/F) 7/3 61/25 NS
Mode of infection 6 IVDA; 1
post-transfusion; 1
haemophiliac; 2 sporadic
51 IVDA; 9
post-transfusion; 2
haemophiliac; 24 sporadic
NS
Duration of infection
(median (range)) 16 (8–22) 12 (4–42) NS
Alcohol 2 13 NS
HIV 0 3 NS
Hepatitis B virus 0 1 NS
Normal ALT 7 8 <0.001
Disease state 1 Cirrhosis; 9 chronic
hepatitis
9 Cirrhosis; 77 chronic
hepatitis NS
Histological activity index 6 (1–13) 8 (1–14) NS
Riba-3 bands 9 Present (>2 bands); 1
ind – NS
HCV genotype 4 Genotype 1; 1 genotype
2; 4 genotype 3; 1
genotype 4
37 Genotype 1; 11
genotype 2; 32 genotype
3; 6 genotype 4 NS
Figure 1 Intrahepatic virus levels in patients repeatedly
HCV RNA positive (n=86) or negative (n=12) by
RT-PCR.
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Figure 2 Intrahepatic virus levels by HCV genotype. 1, genotype 1a (n=40); 2, genotype
1b (n=1); 3, genotype 2a (n=2); 4, genotype 2b (n=10); 5, genotype 3 (n=36); 6, genotype
4 (n=7).
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separated by agarose gel electrophoresis using
4% Metaphor agarose (FMC BioProducts).
Phylogenetic comparisons of sequences in the
conserved region of the genome confirm that
5'-NCR can be used to distinguish the six
major genotypes.38
QUANTITATION OF HCV LEVELS IN SERUM
SAMPLES AND LIVER TISSUE
Liver tissue samples were quantified by limiting
dilution of cDNA reverse transcribed from
HCV RNA. This has been described in detail
elsewhere.40 41 Briefly, 5 µl of HCV cDNA was
diluted in a series (five for serum samples and
seven for liver biopsy samples) of 10-fold steps
which allowed cDNA to be quantified to within
1 log of its actual concentration. Further
refinement of the quantitation by adding a spe-
cific volume of cDNA to a number of replicate
PCR reactions, thus giving a Poisson distribu-
tion of positive and negative samples, and
allowing the exact HCV concentration to be
determined, has been shown not to be
necessary to improve the accuracy of the assay
if the nearest whole log only is required.
Positive controls (4 × 105 copies/ml) were
run concurrently with each limiting dilution
analysis to ensure reproducibility of the assay.
Serum samples from healthy individuals with-
out risk factors were examined for HCV RNA
as negative controls.
The previously established eYciency of 5%
for the reverse transcription reaction was
assumed in this assay. Centrifugation of 0.1 ml
serum provided a detection sensitivity of
approximately 4000 HCV copies/ml. To in-
crease the sensitivity of the PCR method, sam-
ples that were negative at this level of detection
(less than 4000 HCV/ml) were further ana-
lysed by centrifugation of 0.5 ml (detection
sensitivity: 800 HCV copies/ml) or if necessary
5.0 ml (detection sensitivity: 80 HCV copies/
ml) of serum.
The limiting dilution assay has been shown
to have significant reproducibility when multi-
ple samples are tested in duplicate, using RNA
extracted on separate days from separate
aliquots of sample and diVerent batches of rea-
gents. Likewise a significant correlation has
been shown between limiting dilution and
three commercial assays: bDNA1, bDNA2
(Chiron, Emeryville, California), and Roche
Monitor. Furthermore, when the quantity of
transcripts of genotypes 1, 2, and 3 was
compared by limiting dilution, there was a sta-
tistically similar distribution of the quantity of
virus. This indicates that no correction factor
for diVerent genotypes (1, 2, and 3) is required
when using this assay for quantitating hepatitis
C virus levels.42
HISTOLOGICAL ANALYSIS
Liver biopsy specimens from all 98 patients
were available for assessment by a single
observer blinded to the clinical and serological
data. Histological features were graded accord-
ing to the classifications of Knodell et al,43
assessing portal, periportal, and lobular inflam-
mation as well as fibrosis.
STATISTICAL ANALYSIS
The results were analysed by non-parametric
tests where appropriate: the ÷2 or Fisher’s exact
test, the Mann-Whitney test, or Kruskal-Wallis
probability tests.
Results
During an eighteen month period, intrahepatic
HCV levels of 12 patients repeatedly negative
for HCV RNA in serum by RT-PCR (on three
separate occasions) were assessed and com-
pared with 86 patients repeatedly positive for
HCV RNA in serum by RT-PCR.
The relation between intrahepatic HCV lev-
els and the clinicopathological characteristics
of chronic HCV infection was then investi-
gated.
VIRUS FACTORS
Serum RT-PCR for HCV RNA
Ten out of 12 patients RT-PCR negative for
HCV RNA in serum were RT-PCR positive in
the liver; however, this group had both a
significantly lower intrahepatic HCV level
(p<0.0001) (fig 1) and a significantly lower
serum aminotransferase level (p<0.001) (table
1) than the remaining 86 patients. Table 1
illustrates the demographic and virological
similarity between the serum RT-PCR negative
and positive patients. There was no significant
correlation between virus levels and any
parameter.
HCV genotype
Hepatitis C virus genotypes were assessed in 96
patients by restriction fragment length poly-
morphism analysis of HCV cDNA. There was
no significant diVerence in intrahepatic virus
levels between patients infected with genotype
1 (n=41), genotype 2 (n=12), genotype 3
(n=36), and genotype 4 (n=7) (fig 2). The two
patients who were RT-PCR negative in both
liver and serum could not be genotyped.
LIVER HISTOLOGY
Ten patients had cirrhosis at diagnostic lapar-
oscopy and liver biopsy. The remaining 88
Table 2 Correlation coeYcients between intrahepatic virus levels and patient age, duration
of infection, serum aminotransferase level, and histological activity index
Parameter
Population median
(range)
Pearson correlation
coeYcient p Value
Age (y) 37 (24–65) 0.0624 0.55
Serum aminotransferase 72 (13–577) 0.091 0.391
Duration of infection (y) 12 (4–42) −0.0661 0.592
Histological activity index 8 (1–14) 0.082 0.47
Table 3 Qualitative histological findings and alanine aminotransferase (ALT) and
intrahepatic HCV levels in serum RT-PCR HCV RNA negative patients with persistent
hepatic infection
Patient no ALT (U/l)
Log liver
virus level
(copies/g) Steatosis
Portal
inflammation
Lobular
information
Periportal
fibrosis
1 37 4.72 – + + –
2 11 5.42 – – + –
3 69 4.10 – + + +
4 32 6.57 – + + –
5 35 7.68 – + + +
6 37 4.44 – + + +
7 56 9.28 – + + +
8 40 4.49 – – + –
9 105 4.22 – + + +
10 19 5.58 – + +
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patients had macroscopic and histological fea-
tures of ongoing inflammatory activity in keep-
ing with chronic HCV hepatitis. Neither the
histological severity nor the histological activity
index (HAI) aVected the intrahepatic virus lev-
els (fig 3; table 2).
Table 3 illustrates the descriptive histological
findings in the 10 patients who were serum
RT-PCR negative for HCV RNA, but RT-PCR
positive in the liver.
PATIENT FACTORS
Mode and duration of infection
Intrahepatic HCV levels were unaVected by
either the mode or duration of infection (fig 4;
table 2).
Serum aminotransferase
There was no significant correlation between
serum ALT and intrahepatic HCV levels (table
2).
Cofactors
Coinfection with hepatitis B virus (HBV) or
human immunodeficiency virus (HIV), or
alcohol abuse did not significantly aVect intra-
hepatic HCV levels.
Discussion
The current pandemic of hepatitis C infection
has aVected 1–2% of the world’s population,
and 0.02% of the population of the UK.44
However, it is unclear what proportion of
patients have a self limiting illness, successfully
eliminate HCV, and then become immune to
reinfection; furthermore, the host or virus fac-
tors increasing the likelihood of successful
elimination, and the baseline markers of this
process are unknown. The prognostic signifi-
cance of individual clinical, epidemiological,
and virological parameters in this context has
also not been clarified. For these reasons, we
assessed the clinical, histological, and virologi-
cal profile of 98 consecutive patients, present-
ing for staging of their liver disease by diagnos-
tic laparoscopy and liver biopsy and further
compared a unique serum HCV cDNA PCR
negative population of 12 patients with a larger
subpopulation of HCV cDNA PCR positive
patients. Our data have shown that repeatedly
negative RT-PCR for HCV RNA did not indi-
cate complete hepatic elimination of HCV in
10 out of 12 (87.5%) of our patients; also that
intrahepatic HCV levels were not determined
by either host factors (age of patient, mode or
duration of infection, concurrent alcohol
abuse, or concurrent HBV/HIV infection) or
by virus factors (HCV genotype).
For confirmation of positive anti-HCV test
results, recombinant immunoblot assays were
developed; RIBA-3 results are interpreted as
“positive” when one or more bands are
positive, and “indeterminate” when only one
band is positive. A high proportion (75–80%)
of RIBA-3 positive patients have viraemia as
detected by RT-PCR for HCV RNA. It has
been suggested that RIBA-3 positive but
RT-PCR negative patients may have cleared the
virus from the circulation after a previous
infection, may be viraemic below the RT-PCR
detection level, or may represent false positive
anti-HCV reactivity. Previous studies have
indicated that RT-PCR negative/anti-HCV
positive patients correlate with absence of
inflammation on liver biopsy specimens, and
this observation probably indicates clearance of
the virus.45 In our study 10 out of 12 (87.5%)
patients were RT-PCR positive for HCV RNA
in liver tissue, but RT-PCR negative in serum
and all had ongoing inflammation diagnosed at
diagnostic laparoscopy and liver biopsy. This
favours the hypothesis that these patients were
viraemic below the RT-PCR detection level in
serum (in our case, this was a detection sensi-
tivity of 800 HCV copies/ml in 0.5 ml of
serum); furthermore, patients RT-PCR positive
for HCV RNA in serum had a significantly
higher intrahepatic HCV level than patients
RT-PCR negative for HCV RNA in serum.
Remarkably, comparison of the serum RT-
PCR negative and positive subpopulations
indicated that they were statistically similar in
terms of demographic, histological, and viro-
logical data; the serum RT-PCR negative
subpopulation did however have a significantly
lower serum ALT than the RT-PCR positive
patients despite the poor correlation between
liver virus level and ALT overall. Possibly,
the serum RT-PCR negative patients, with
their concurrent lower intrahepatic HCV level
and ALT, may have a lower grade hepatic
Figure 3 Intrahepatic virus levels by disease state.
1, Chronic hepatitis; 2, cirrhosis.
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Figure 4 Intrahepatic virus levels according to mode of transmission of HCV. 1, IVDA
(n=58); 2, post-transfusion (n=10); 3, haemophiliac (n=4); 4, sporadic (n=26).
10
9
8
7
6
4
5
21
Mode of transmission of HCV infection
Lo
g
 (
liv
er
 H
C
V;
 c
o
p
ie
s/
g
)
0 3 4
Intrahepatic HCV levels in chronic HCV infection 573
inflammation; however, there is no significant
diVerence in HAI between the populations.
Therefore, the prognostic importance of these
data is that serum RT-PCR negative patients
with chronic HCV infection should be followed
up indefinitely, and at present there is no indi-
cation that they are at a lower risk of severe liver
disease in the future. We propose follow up
studies assessing these patients for the presence
of very low levels of viraemia by increasing the
detection sensitivity to 80 copies HCV/ml in 5
ml of serum or even eight copies HCV/ml in 50
ml of serum.
The second important finding of this report
was the absence of a significant relation
between host or virus factors and intrahepatic
HCV levels; thus the significance of a single
assessment of intrahepatic HCV RNA in terms
of diagnosis and prognosis remains unclear.
Indeed, in contrast with similar serum studies,
this finding corresponds to previous intrahe-
patic studies which have shown no correlation
between HCV RNA levels and liver injury.19–29
The largest of these studies utilised three
diVerent methodologies for quantitation of
HCV RNA (Dot-Blot PRC, end point titra-
tion, and Roche Amplicor Monitor Assay),
examined interassay and intra-assay variability
in detail, and showed no significant association
with the degree of liver injury.29 There are at
present no data measuring viral replication in
addition to the total HCV load and its eVect on
liver injury. Recently, new techniques have
been developed to overcome the
methodological problems associated with de-
tection of true replicative (negative or anti-
sense) HCV RNA levels, but their ability to
quantitate specifically HCV RNA over a wide
range of HCV levels is still limited.46 47
There was no correlation in our study
between HCV RNA levels in liver and other
demographic factors such as sex, age, duration
of illness, and mode of infection. These data
confirm previous studies on liver virus levels
but contrast with studies examining serum lev-
els of HCV RNA where increased levels have
been shown in relation to age, sex, mode, and
duration of infection.10–18 This observed dis-
crepancy may be explained by a combination of
factors: contribution to serum HCV RNA lev-
els from virus in other tissues (and from
necrotic liver tissue), HCV RNA in serum
immune complexes, technical variation be-
tween methods, diVerent populations studied,
and time dependent fluctuation in serum HCV
levels. Certainly analysis based on serum stud-
ies is more diYcult to interpret than that based
on intrahepatic studies.
In addition, we did not show an eVect of
HCV genotype on intrahepatic virus levels.
This conflicts with data indicating that geno-
type 1b generally has higher HCV RNA levels
in serum and liver and therefore a higher virae-
mic load than other genotypes tested.30–32 How-
ever, genotypic analysis of our data was limited
by the presence of only one patient infected
with genotype 1b, while 19 patients were
infected with genotype 1a.
In conclusion, we have successfully shown
that repeatedly negative RT-PCR for HCV
RNA in serum does not indicate complete
hepatic elimination of HCV. Indeed, these
patients have a similar clinical, pathological,
and epidemiological profile to serum RT-PCR
positive patients; their prognosis and require-
ments for full staging of liver disease are thus
likely to be similar, and further follow up is
mandatory. However, we were unable to show
any significant associations between intrahe-
patic HCV levels and other clinicopathological
parameters. Importantly, these data support
the hypothesis that HCV does not cause liver
disease by a cytopathic process; they also illus-
trate the limitations of a single assessment of
HCV levels. Clearly, there is a requirement for
sequential studies of chronic HCV infection in
terms of molecular virological and clinical
parameters, before the clinical significance of
intrahepatic HCV levels is established.
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